Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Ocean Biomedical Inc. (OCEA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: OCEA (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -8.97% | Avg. Invested days 72 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.64M USD | Price to earnings Ratio - | 1Y Target Price 18.5 |
Price to earnings Ratio - | 1Y Target Price 18.5 | ||
Volume (30-day avg) 56029148 | Beta 1.53 | 52 Weeks Range 0.05 - 3.20 | Updated Date 03/8/2025 |
52 Weeks Range 0.05 - 3.20 | Updated Date 03/8/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -681.99% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 20527985 | Price to Sales(TTM) - |
Enterprise Value 20527985 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -9.48 | Shares Outstanding 34649000 | Shares Floating 7517457 |
Shares Outstanding 34649000 | Shares Floating 7517457 | ||
Percent Insiders 71.99 | Percent Institutions 11.62 |
Analyst Ratings
Rating - | Target Price 17.45 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Ocean Biomedical Inc.
Company Overview
History and Background
Ocean Biomedical Inc. was founded relatively recently, focusing on developing therapies for oncology and infectious diseases. It has rapidly expanded its pipeline through acquisitions and licensing agreements.
Core Business Areas
- Oncology: Developing therapies targeting cancer, including immune-oncology approaches.
- Infectious Diseases: Developing therapies targeting infectious diseases, including malaria.
- Fibrosis: Developing therapies for fibrotic diseases.
Leadership and Structure
The leadership team comprises experienced executives and scientists with expertise in drug development and commercialization. The organizational structure is built around functional teams, including research, development, and commercialization.
Top Products and Market Share
Key Offerings
- Malaria Vaccine (preclinical): Developing a malaria vaccine targeting the PfEMP1 protein. This is currently in preclinical stages. Competitors are GSK with Mosquirix and BioNTech is in early development.
- Anti-Cancer Chitinase Inhibitor (preclinical): Developing small molecule chitinase inhibitors that may be useful as anti-cancer agents and for treating fibrosis. The program is in preclinical stages. Competitors include Bio-Path Holdings (BPTH) which is in Phase 1 stages
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, regulatory hurdles, and intense competition. The oncology and infectious disease markets are large and growing.
Positioning
Ocean Biomedical is positioned as an emerging biotechnology company focused on innovative therapies. Its competitive advantage lies in its diverse pipeline and strategic collaborations.
Total Addressable Market (TAM)
The total addressable market is estimated at hundreds of billions of dollars across oncology and infectious diseases. Ocean Biomedical is positioned to capture a small but potentially significant share.
Upturn SWOT Analysis
Strengths
- Diverse Pipeline
- Experienced Leadership
- Strategic Collaborations
- Novel Therapeutic Approaches
Weaknesses
- Early Stage Development
- Limited Financial Resources
- Reliance on Partnerships
- Limited clinical trial data
Opportunities
- Partnerships with Larger Pharma Companies
- Positive Clinical Trial Results
- Expansion into New Therapeutic Areas
- Breakthrough Therapy Designations
Threats
- Clinical Trial Failures
- Regulatory Hurdles
- Competition from Established Players
- Funding Constraints
Competitors and Market Share
Key Competitors
- MRNA
- PFE
- JNJ
- GSK
- BNTX
Competitive Landscape
Ocean Biomedical faces intense competition from established pharmaceutical companies and other emerging biotechnology companies. Its advantages include its innovative therapies and strategic collaborations, but its disadvantages include its limited financial resources and early stage development.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by pipeline expansion and increased R&D spending.
Future Projections: Future growth is dependent on clinical trial success, regulatory approvals, and commercialization of its therapies. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include securing funding, advancing preclinical programs, and expanding collaborations.
Summary
Ocean Biomedical is an early-stage biotech company with a promising pipeline but faces significant risks. Its success hinges on advancing its therapies through clinical trials and securing partnerships. The company's innovative approaches offer potential for significant returns, but investors should be aware of the inherent volatility of the biotech sector. Securing funding is vital for its success and is an area that it needs to keep an eye on.
Similar Companies
- MRNA
- VIR
- BNTX
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Investment decisions should be based on individual due diligence and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Ocean Biomedical Inc.
Exchange NASDAQ | Headquaters Providence, RI, United States | ||
IPO Launch date 2021-11-08 | CEO & Director Dr. M. Michelle Berrey M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.oceanbiomedical.com |
Full time employees - | Website https://www.oceanbiomedical.com | ||
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company develops an antibody therapeutic product candidate inhibiting Chi3l1, and a bi-specific antibody product candidate inhibiting Chi3l1 plus PD-1 and CTLA-4 for the treatment of non-small cell lung cancer and glioblastoma multiforme; and a small molecule product candidate targeting Chit1 for the treatment of idiopathic pulmonary fibrosis and Hermansky-Pudlak syndrome. It is also developing three product candidates based on the whole proteome differential screening target discovery platform, including a malaria vaccine candidate against plasmodium falciparum Schizont Egress Antigen-1 (PfSEA-1) and/or against plasmodium falciparum Glutamic Acid Rich Protein (PfGARP); a humanized mAb malaria therapeutic candidate targeting PfGARP; and a small molecule malaria product candidate targeting PfGARP. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.